475 related articles for article (PubMed ID: 25258345)
1. Reduced alpha-synuclein in cerebrospinal fluid in synucleinopathies: evidence from a meta-analysis.
Sako W; Murakami N; Izumi Y; Kaji R
Mov Disord; 2014 Nov; 29(13):1599-605. PubMed ID: 25258345
[TBL] [Abstract][Full Text] [Related]
2. Neurofilament light chain level in cerebrospinal fluid can differentiate Parkinson's disease from atypical parkinsonism: Evidence from a meta-analysis.
Sako W; Murakami N; Izumi Y; Kaji R
J Neurol Sci; 2015 May; 352(1-2):84-7. PubMed ID: 25868897
[TBL] [Abstract][Full Text] [Related]
3. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
4. CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders.
Mondello S; Constantinescu R; Zetterberg H; Andreasson U; Holmberg B; Jeromin A
Parkinsonism Relat Disord; 2014 Apr; 20(4):382-7. PubMed ID: 24507721
[TBL] [Abstract][Full Text] [Related]
5. Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders.
Hall S; Öhrfelt A; Constantinescu R; Andreasson U; Surova Y; Bostrom F; Nilsson C; Håkan W; Decraemer H; Någga K; Minthon L; Londos E; Vanmechelen E; Holmberg B; Zetterberg H; Blennow K; Hansson O
Arch Neurol; 2012 Nov; 69(11):1445-52. PubMed ID: 22925882
[TBL] [Abstract][Full Text] [Related]
6. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease.
Holmberg B; Rosengren L; Karlsson JE; Johnels B
Mov Disord; 1998 Jan; 13(1):70-7. PubMed ID: 9452329
[TBL] [Abstract][Full Text] [Related]
7. Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies.
Foulds PG; Yokota O; Thurston A; Davidson Y; Ahmed Z; Holton J; Thompson JC; Akiyama H; Arai T; Hasegawa M; Gerhard A; Allsop D; Mann DM
Neurobiol Dis; 2012 Jan; 45(1):188-95. PubMed ID: 21856424
[TBL] [Abstract][Full Text] [Related]
8. Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease.
Tateno F; Sakakibara R; Kawai T; Kishi M; Murano T
Alzheimer Dis Assoc Disord; 2012; 26(3):213-6. PubMed ID: 22037599
[TBL] [Abstract][Full Text] [Related]
9. CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.
Constantinides VC; Paraskevas GP; Emmanouilidou E; Petropoulou O; Bougea A; Vekrellis K; Evdokimidis I; Stamboulis E; Kapaki E
J Neurol Sci; 2017 Nov; 382():91-95. PubMed ID: 29111028
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy.
Holmberg B; Johnels B; Blennow K; Rosengren L
Mov Disord; 2003 Feb; 18(2):186-90. PubMed ID: 12539213
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylated α-synuclein and phosphorylated tau-protein in sural nerves may contribute to differentiate Parkinson's disease from multiple system atrophy and progressive supranuclear paralysis.
Rong Z; Shen F; Wang Y; Sun L; Wu J; Zhang H; Yuan Y; Jiang W; Li X; Ji P; Zhang K
Neurosci Lett; 2021 Jun; 756():135964. PubMed ID: 34022266
[TBL] [Abstract][Full Text] [Related]
12. Use of CSF α-synuclein in the differential diagnosis between Alzheimer's disease and other neurodegenerative disorders.
Wang ZY; Han ZM; Liu QF; Tang W; Ye K; Yao YY
Int Psychogeriatr; 2015 Sep; 27(9):1429-38. PubMed ID: 25851548
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy.
Compta Y; Giraldo DM; Muñoz E; Antonelli F; Fernández M; Bravo P; Soto M; Cámara A; Torres F; Martí MJ;
Parkinsonism Relat Disord; 2018 Jan; 46():16-23. PubMed ID: 29107645
[TBL] [Abstract][Full Text] [Related]
14. Diffusion-weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple-system atrophy from progressive supranuclear palsy.
Paviour DC; Thornton JS; Lees AJ; Jäger HR
Mov Disord; 2007 Jan; 22(1):68-74. PubMed ID: 17089396
[TBL] [Abstract][Full Text] [Related]
15. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
[TBL] [Abstract][Full Text] [Related]
16. CSF α-synuclein does not differentiate between parkinsonian disorders.
Aerts MB; Esselink RA; Abdo WF; Bloem BR; Verbeek MM
Neurobiol Aging; 2012 Feb; 33(2):430.e1-3. PubMed ID: 21236518
[TBL] [Abstract][Full Text] [Related]
17. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy.
Quattrone A; Nicoletti G; Messina D; Fera F; Condino F; Pugliese P; Lanza P; Barone P; Morgante L; Zappia M; Aguglia U; Gallo O
Radiology; 2008 Jan; 246(1):214-21. PubMed ID: 17991785
[TBL] [Abstract][Full Text] [Related]
18. [Iodine 123-labeled meta-iodobenzylguanidine myocardial scintigraphy in the cases of idiopathic Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy].
Yoshita M; Hayashi M; Hirai S
Rinsho Shinkeigaku; 1997 Jun; 37(6):476-82. PubMed ID: 9366173
[TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal Fluid Levels of 5-Hydroxyindoleacetic Acid in Parkinson's Disease and Atypical Parkinsonian Syndromes.
Kaiserova M; Chudackova M; Prikrylova Vranova H; Mensikova K; Kastelikova A; Stejskal D; Kanovsky P
Neurodegener Dis; 2021; 21(1-2):30-35. PubMed ID: 34695830
[TBL] [Abstract][Full Text] [Related]
20. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.
Magdalinou NK; Paterson RW; Schott JM; Fox NC; Mummery C; Blennow K; Bhatia K; Morris HR; Giunti P; Warner TT; de Silva R; Lees AJ; Zetterberg H
J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1240-7. PubMed ID: 25589779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
